CPC Main Group Additional Only
C12Q 2600/00 Oligonucleotides characterized by their use
15 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112 Disease subtyping, staging or classification
- C12Q 2600/118 Prognosis of disease development
- C12Q 2600/124 Animal traits, i.e. production traits, including athletic performance or the like
- C12Q 2600/13 Plant traits
- C12Q 2600/136 Screening for pharmacological compounds
- C12Q 2600/142 Toxicological screening, e.g. expression profiles which identify toxicity
- C12Q 2600/148 Screening for cosmetic compounds
- C12Q 2600/154 Methylation markers
- C12Q 2600/156 Polymorphic or mutational markers
- C12Q 2600/158 Expression markers
- C12Q 2600/16 Primer sets for multiplex assays
- C12Q 2600/166 Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q 2600/172 Haplotypes
- C12Q 2600/178 miRNA, siRNA or ncRNA
Top Applicants
Top 10 applicants by patent filingsfor class C12, 2013–2023, worldwide · Source: EPO PATSTAT
- HARVARD UNIVERSITY US 8,321
- CHINESE ACADEMY OF SCIENCES 7,486
- UNIVERSITY OF CALIFORNIA US 7,320
- REGENERON PHARMACEUTICALS US 5,003
- INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) FR 4,292
- UNIVERSITY OF PENNSYLVANIA US 4,213
- CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) FR 4,113
- JIANGNAN UNIVERSITY 3,961
- ROCHE CH 3,792
- ILLUMINA US 3,692